Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 221,98 € (+5,00%). La mediana è 226,85 € (+7,31%).
| Acquista |
31 |
| Mantieni |
11 |
| Vendi |
1 |
Discussioni nella community
Tradotto (originale in tedesco)
Satellite DividendiCiao, Vorrei mostrare uno dei miei portfolio satellite per ricevere feedback o come esempio di apprendimento, https://app.parqet.com/p/6666e0d2ea0c80cf00f4487b Si vede un portafoglio dividendi di TR…
Benjamin V in Portfolio Roasts
4 12- Ein potenzieller deutscher 10-Bagger? Chapters Group im Fokus
Hallo zusammen, ich möchte euch heute ganz kurz Chapters Group aus Hamburg vorstellen. Viele vergleichen das Unternehmen bereits mit einer frühen Constellation Software oder Danaher, also einem…
Peter Andres II in Schnack
4 10 - Holdings statt ETF. Habt Ihr Empfehlungen?
Hallo Zusammen, Hi Community, ich habe eine Frage bei der vielleicht einige mit Tips helfen können. Ich habe gerade mein Kapital in eine vermögensverwaltende GmbH verlagert und bin dort mit Aktien…
T TraderGranny IV in Schnack
1 8 - Position lässt sich nicht löschen
Hallo Community, seit einigen Tagen versuche ich meine Position “Veralto” (A3ES7Q) zu löschen. Sobald ich auf löschen klicke, werde ich gefragt, ob ich das wirklich möchte. Wenn ich dann wieder auf…
Parqet Nutzer I in Schnack
0 3 - Hallo, nach einem Spin-off bei 3M und A.P. Moller-Mearsk B werden mir falsche Einstiegskurse angezeigt. Ich kann das nicht korrigieren. Pflege ich die PDF Datei neu ein, kommen weiter Automatisch die falschen Einstiegskurse. Gibt es schon ein Lösung?
PN Parqet Nutzer IV in Schnack
1 27
Notizie Vai al feed delle notizie
Danaher raises revenue and profit in third quarter and lifts outlook
Danaher reports a Q3 revenue increase of 8.5% to $6.6 billion and net income of $1.2 billion. Adjusted earnings per share were $2.11, beating the $1.91 expectation; operating cash flow was $1.9 billion and free cash flow rose 19% to $1.63 billion. As a result, Danaher raises its full-year guidance for adjusted EPS to $8.57–$8.62; the stock gains and also lifts Sartorius' preferred share higher. » Altro su deraktionaer.de
Danaher highlighted by Aristotle Capital for durable healthcare growth
Aristotle Value Equity Fund flagged Danaher as a core holding, citing disciplined capital allocation, the Danaher Business System, strong free cash flow and a high share of recurring consumables revenue. The letter notes Danaher’s transformation into a focused healthcare company through spinoffs and acquisitions such as Pall, Cepheid and Cytiva, which bolstered predictable workflow-based revenues. Danaher shares gained about 10.6% over one month and traded near $215 with a market cap around $155.6 billion; the fund said its overall underperformance in Q2 was due to limited exposure to the AI infrastructure rally. » Altro su finance.yahoo.com
Danaher shows signs of life sciences recovery after several weak years
Danaher reported improving life‑sciences trends with its Life Sciences unit delivering the strongest performance in years and bioprocessing orders growing mid‑teens, suggesting underlying demand for consumables and equipment is solid. Management said just over $100 million of revenue shifted into next year, indicating delayed rather than lost customer projects, but cut the upper end of its full‑year core revenue growth outlook to 4% due to weakness in biotechnology and respiratory testing. The company’s recovery appears broadening but remains uneven across end markets, leaving investors to weigh near‑term cyclical improvements against lingering pockets of weakness. » Altro su finance.yahoo.com
Danaher disappoints in quarter, Sartorius stock heavily hit
Danaher's quarterly report disappointed in diagnostics and bioprocessing, and the stock fell by about 14 percent. Weak operating performance and timing delays on customer projects in bioprocessing also weighed on Sartorius's stock, which lost up to 12 percent. Analysts see short-term disappointments and a muted outlook for Q3 but consider the long-term prospects intact and view the price weakness partly as a buying opportunity, with revenue growth expected to accelerate from 2027. » Altro su de.investing.com
Danaher viewed as a top non-tech buy as Masimo wins FDA clearance and brokers express mixed views
Analysts name Danaher among the best non-tech stocks to buy while brokers hold mixed stances. Masimo announced FDA 510(k) clearance for an opioid‑induced respiratory depression detection feature integrated into its Radius VSM wearable monitor, a development tied to Danaher’s diagnostics exposure. Wolfe Research downgraded Danaher to Peer Perform citing uncertainty over the Masimo transaction, while Piper Sandler initiated coverage awaiting new growth catalysts. Danaher continues to operate across Diagnostics, Biotechnology, Life Sciences and Environmental and Applied Solutions. » Altro su finance.yahoo.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 5,75 Mld | 11,24% |
| Utile lordo | 3,37 Mld | 11,89% |
| Utile netto | 1,08 Mld | 39,74% |
| EBITDA | 1,11 Mld | 26,25% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 148,76 Mld € |
Numero di azioni | 703,53 Mln |
Massimo/minimo a 52 settimane | 220,32 € - 146,03 € |
Rendimento da dividendo | 0,62% |
Dividendi TTM | 1,31 € |
Beta | 0,80 |
Rapporto P/E | 38,08 |
Rapporto PEG | 1,50 |
Rapporto P/B | 3,06 |
Rapporto P/S | 6,40 |
Profilo aziendale
Danaher Corporation progetta, produce e commercializza prodotti e servizi professionali, medicali, industriali e commerciali in tutto il mondo. La società opera attraverso tre segmenti: Life Sciences, Diagnostics ed Environmental & Applied Solutions. Il segmento Life Sciences fornisce spettrometri di massa; sistemi di citometria a flusso, genomica, automazione di laboratorio, centrifugazione, conteggio e caratterizzazione delle particelle; microscopi; materiali di consumo per la genomica; e Gene and Cell Therapy. Questo segmento offre inoltre tecnologie, materiali di consumo e servizi per la bioprocessazione, nonché tecnologie di filtrazione, separazione e purificazione destinate ad aziende farmaceutiche e biofarmaceutiche, del settore alimentare e delle bevande, medicali e delle scienze della vita, oltre che a università, facoltà di medicina e istituti di ricerca, e a vari produttori industriali. Il segmento Diagnostics fornisce sistemi di chimica clinica, immunodosaggio, microbiologia e automazione, nonché prodotti diagnostici per ematologia, biologia molecolare, cure acute e patologia. Questo segmento offre strumenti clinici, reagenti, materiali di consumo, software e servizi per ospedali, studi medici, laboratori di riferimento e altri contesti di terapia intensiva. Il segmento Environmental & Applied Solutions offre strumentazione, materiali di consumo, software, servizi e sistemi di disinfezione per analizzare, trattare e gestire acqua ultrapura, potabile, industriale, di scarico, di falda, di sorgente e marina in applicazioni residenziali, commerciali, industriali e legate alle risorse naturali. Questo segmento fornisce inoltre strumenti, software, servizi e materiali di consumo per la gestione del colore e dell'aspetto, la progettazione e il controllo qualità degli imballaggi, la trasformazione di imballaggi, la stampa, la marcatura, la codifica e la tracciabilità per prodotti di consumo, farmaceutici e industriali. La società era precedentemente nota come Diversified Mortgage Investors, Inc. e nel 1984 ha cambiato denominazione in Danaher Corporation. Danaher Corporation è stata fondata nel 1969 ed ha sede a Washington, nel District of Columbia.
| Nome | Danaher |
| CEO | Julie Sawyer Montgomery |
| Sede centrale | Washington,
dc Stati Uniti |
| Sito web | |
| Settore | Sanità |
| Industria | Attrezzature e forniture sanitarie |
| Quotazione in borsa | 21/09/2015 |
| Dipendenti | 59.000 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NYSE | DHR |
London Stock Exchange | 0R2B.L |
XETRA | DAP.DE |
Frankfurt | DAP.F |
Düsseldorf | DAP.DU |
Milan | 1DHR.MI |
London | 0R2B.L |
SIX | DHR.SW |
München | DAP.MU |
Wien | DHRC.VI |